{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-020589","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2024-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.402051+00:00","generated_at":"2026-06-01T03:57:23.293152+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clene: CNM-Au8 shows 60% reduced death risk (HR 0.431, p=0.0002) and 28% NfL reduction in ALS trial OLE","bullets":["Survival analysis of CNM-Au8 30 mg vs matched PRO-ACT controls up to 3.5 years: HR 0.431 (95% CI 0.276-0.672, p=0.0002).","NfL responder subset (n=55) showed average 28% NfL reduction at Week 76 (GMR 0.72, p<0.0001), indicating decreased axonal loss.","More than 650 patient-years of CNM-Au8 treatment exposure with no identified safety signals.","Data presented at 2024 ENCALS meeting; includes up to 42 months survival follow-up and 76 weeks biomarker results."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-020589","json":"https://secwatch.observer/filing/0001437749-24-020589.json","markdown":"https://secwatch.observer/filing/0001437749-24-020589.md","text":"https://secwatch.observer/filing/0001437749-24-020589.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924020589/0001437749-24-020589-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924020589/clnn20240611_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:57:23.293152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}